• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tevogen Bio Holdings Inc. - Warrant (NQ: TVGNW )

    0.0248 UNCHANGED
    Streaming Delayed Price Updated: 2:59 PM EDT, Aug 28, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 0.0248
    Bid (Size) 0.0150 (100)
    Ask (Size) 0.0248 (241)
    Prev. Close 0.0248
    Today's Range 0.0248 - 0.0248
    52wk Range 0.0141 - 0.2825
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Tevogen Bio Secures $6 Million Series C Preferred Stock Investment
    From Tevogen Bio Inc
    Via GlobeNewswire
    CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
    From Tevogen Bio Inc
    Via GlobeNewswire

    Performance

    YTD
    -73.89%
    -73.89%
    1 Month
    +37.78%
    +37.78%
    3 Month
    -38.00%
    -38.00%
    6 Month
    -58.67%
    -58.67%
    1 Year
    -73.89%
    -73.89%

    More News

    Read More
    Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company’s Ability to Continue as a Going Concern, Eliminates Series B Preferred Shares
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public Health
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s Founding CEO, Ryan Saadi, Expresses Conviction in Company’s Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive Securities
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share Buyback
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina Ayanian
    From Tevogen Bio Inc
    Via GlobeNewswire
    Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social Responsibility
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive Securities
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood Advances
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Set to Join Russell 3000® Index
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
    From Tevogen Bio Inc
    Via GlobeNewswire
    CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement Event
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement Event
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Reports First Quarter 2024 Financial Results
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Announces Full Year 2023 Financial Results and Upcoming Operational Objectives
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio CEO Highlights Expected Reporting of a $94.9 Million Liability Elimination, AI Initiative, and Leadership Appointments
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio’s Chief Scientific Officer Speaks on the Harnessing of Cytotoxic T Lymphocytes (CTLs) to Target Cancers
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Appoints Tapan V Shah as Head of Investor Relations and Corporate Development
    From Tevogen Bio Inc
    Via GlobeNewswire
    Tevogen Bio Reports Series A-1 Preferred Stock Investment at $10 Conversion Price
    From Tevogen Bio Inc
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.